Biologic Augmentation of Osteochondral Allograft Transplantation in the Knee
brief summary
This prospective, single-center pilot study will evaluate biologic augmentation during osteochondral allograft transplantation of the knee using a combination of bone marrow aspirate concentrate (BMAC) and Arthrex AlloSync Pure. Approximately 10 adults undergoing osteochondral allograft transplantation for focal osteochondral defects of the medial or lateral femoral condyle will be enrolled. During surgery, BMAC will be collected from the tibial tubercle and mixed with Arthrex AlloSync Pure. The mixture will be applied to the recipient socket and graft plug before allograft implantation. The primary objective is to assess osteochondral allograft incorporation using magnetic resonance imaging (MRI) at 6 months after surgery. Secondary outcomes include MRI-based graft incorporation at 12 weeks and, when clinically indicated, 12 months; knee function and pain measured using the Knee Injury and Osteoarthritis Outcome Score (KOOS) and Visual Analog Scale (VAS); radiographic graft healing; and postoperative complications and adverse events during one year of follow-up.
detailed description
Osteochondral allograft (OCA) transplantation is an established treatment for large focal cartilage and osteochondral defects of the knee. Successful clinical outcomes depend on graft viability, osseous integration, and restoration of the articular surface. Biologic augmentation using bone marrow aspirate concentrate (BMAC) has been investigated as a strategy to improve graft incorporation, but available clinical evidence remains limited and inconsistent.
This prospective, single-center pilot case series will evaluate graft incorporation and clinical outcomes following osteochondral allograft transplantation augmented with a combination of Arthrex AlloSync Pure and BMAC.
Approximately 10 adult patients scheduled for OCA transplantation of the medial or lateral femoral condyle with Dr. Jeffrey Macalena or Dr. Bradley Nelson will be recruited at the University of Minnesota and M Health Fairview Clinics and Surgery Center.
During the planned surgical procedure, bone marrow will be aspirated from the tibial tubercle and processed to obtain BMAC. The BMAC will be mixed with Arthrex AlloSync Pure to create a biologic slurry. This mixture will be applied to the base of the recipient socket and along the walls of the graft plug before implantation of the osteochondral allograft.
Participants will be followed for approximately one year after surgery. Follow-up assessments will occur at approximately 1 week, 6 weeks, 12 weeks, 6 months, and 1 year. Patient-reported outcome measures will include the Knee Injury and Osteoarthritis Outcome Score (KOOS) and Visual Analog Scale (VAS) for pain.
MRI evaluations will be performed at 12 weeks and 6 months after surgery, with additional MRI at 12 months for participants with incomplete graft incorporation at the 6-month assessment. MRI findings will be evaluated using the Osteochondral Allograft MRI Scoring System (OCAMRISS) and other indicators of graft incorporation. Standard-of-care radiographs will also be reviewed to assess graft healing.
The primary outcome is MRI-based osteochondral allograft incorporation at 6 months after surgery. Secondary outcomes include MRI-based incorporation at other follow-up time points, knee function and pain, radiographic healing, postoperative complications, adverse events, and subsequent procedures related to the index surgery.
Because this is an exploratory pilot study with a small sample size, outcomes will be summarized descriptively. Observed graft incorporation findings may be compared qualitatively with results reported in the published literature. There is no randomized or concurrent control group.
official title
Biologic Augmentation for Osteochondral Allograft Transplantation: A Prospective Case-Series